ML20080R773
| ML20080R773 | |
| Person / Time | |
|---|---|
| Site: | Beaver Valley |
| Issue date: | 02/28/1995 |
| From: | George Thomas DUQUESNE LIGHT CO. |
| To: | NRC OFFICE OF INFORMATION RESOURCES MANAGEMENT (IRM) |
| References | |
| NUDOCS 9503100071 | |
| Download: ML20080R773 (3) | |
Text
-
d 4
I[
Beaver Valley Power Station Shippingport. PA 15077-0004 j
64 FAX GEORGE S. THOMAS Iu$a BYE E ""'
February 28, 1995 Nu -
Diwason I
U. S. Nuclear Regulatory Commission Attention: Document Control Desk Washington, DC 20555-0001
Subject:
Beaver Valley Power S.ation, ~ Unit No. I and No. 2 BV-1 Docket No. 50-334, License No. DPR-66 BV-2. Docket No. 50-412, License No. NPF-73 Unsatisfactory Performance Testing Result In accordance with 10 CFR 26, Appendix A, Section 2.8(e)(4), attached is a report of an unsatisfactory fitness for duty program performance testing result. This report was prepared by MetPath, the contractor who provides HHS-certified laboratory services.
If there are any questions concerning this
- matter, please contact Mr. Gene Edwards of our staff at (412) 393-5288.
Sincerely, bf/b 'w 3 George S. Thomas Attachment cc:
Mr. L. W. Rossbach, Sr. Resident Inspector Mr. T. T. Martin, NRC Region I Administrator Mr. G. E. Edison, Sr. Project Manager l
2.C004, j
[
p DO g
P
4
@~M' MetPath 711 B ngham Street E,
g F
Pittsburgh, Pennsytvania 15203 412-488-7500 a CORNING C~ a :#.v > <
Ms Darlene Kopp Duquesne Light Company Nuclear Group - Medical Section P.O. Box 4 Shippingport, PA 15077 February 9,1995
Dear Ms Kopp:
This letter is in response to the false negative Cocaine blind control submitted by your agency on January 31,1995. The blind control specimen was identified as (B-064056-D).
Following your notification to Dr. Fredrick Fochtman of MetPath Laboratory at 9:30 a.m.
on February 1,1995, I was notified and began a thorough investigation to identify the source of this error.
The error was positively identified as a clerical mistake by a Senior Specimen Processor.
)
Two specimens received from your facility identified as (B-064056-D) and (R-064089-D) were inadvertently switched during the specimen aliquotting process for the initial screening procedure. As a result, the blind control specimen (B-064056-D) was reported to your Medical Review Officer as negative on February 1,1995. The other specimen (R-064089-D) was identified as presumntive positive pending confirmation analysis for j
cocaine metabolites Upon your notification, new aliquots from the original specimen containers listed above were retested by the screening procedure for the presence of cocaine metabolites. The results of the second analysis indicated that the blind control
, specimen identified as (B-064056-D) was indeed a presumptive positive for cocaine metabolites and that specimen number (R-064089-D) was negative.
To further ensure the accuracy of these results, both specimens were tested by our GC/MS (Gas Chromatography / Mass Spectrometry) confirmation analysis procedure for the presence of cocaine metabolite (Benzoylecgonine) The GC/MS results confirmed the presence of Benzoylecgonine in specirnen number (B-064056-D) at a concentration of 641 ng/ml. Specimen number (R-064089-D) confirmed negative for the presence of Benzoylecgonine. On February 2,1995, a corrected report on specimen number (B-064056-D) was forwarded to your Medical Review Officer, Dr. Gregg S Zernich.
I
m1 r.
MitPath t
As part of our internal documentation for corrective action in response to this incident, I personally counseled the individual responsible for the incident. This person has been warned as to the severity of this matter and has been reprimanded for the error. The employee will be retrained by their immediate supervisor according to standard operating procedures I will review all documentation of retraining and will review the individual's performance to ensure an incident such as this does not reoccur. The incident report along with training documentation will become part of the employee's personnel file.
Thank you for your prompt notification pertaining to this matter and be assured that our laboratory will take all necessary steps to prevent reoccurrence of this error. If further documentation is required, please contact me at your earliest convenience.
Respectfully, Brian A. Brunelli Director of Toxicology cc: Lenox Abbott, Ph.D.
Bob Bowden Edward Reeping s
I ij i
{
l L.
_ _ _ _ _ _ _ _ _ _ _ _ _ _.. _ _ _ _ _ _ _ _.. _ - _ _ _ _ _ _ _ _ _ _ _ _ _ _ _